Fig. 6
Combined AII and anti-PDL1 exert enhanced anti-cancer activity in autologous PDX models. A Schematic outline for the generation of TNBC PDX models and evaluation of autologous AII in these models. B Tumor growth of PDX A-derived tumors in female NOG mice treated with either anti-PDL1 alone (n = 3), AII alone (n = 4) or combined AII and anti-PDL1 (n = 4). C Mass of excised PDX A tumors from B. D IHC analysis of tumors 150 days post administration of AII cells demonstrating survival of CD3+ TAII cells in both tumor and spleen when co-treated with anti-PDL1. E Same PDX models as in B, but with larger groups: treated with anti-PDL1 alone (n = 9), AII alone (n = 9) or combined AII and anti-PDL1 (n = 9). F Tumor growth of PDX B-derived tumors in female NOG mice treated with either anti-PDL1 alone (n = 5), AII alone (n = 5) or combined AII and anti-PDL1 (n = 5). G Growth of PDX B in female hIL15 NOG mice when treated with anti-PDL1 alone (n = 5), i.v. AII alone (n = 5) or combined i.v. AII and anti-PDL1 (n = 5). H Tumor mass of excised tumors from G. I IHC analysis of excised tumors from G, showing enhanced PDL1 expression in CD3+ TAII infiltrated tumors. J IHC analysis of excised tumors and spleen from G demonstrating TAII homing to tumor and spleen. K Growth of PDX C in female hIL15 NOG mice when treated with anti-PDL1 alone (n = 7), i.v. AII alone (n = 6) or combined i.v. AII and anti-PDL1 (n = 7). L Mass of excised PDX C tumors from K. In all experiments mice were administered 200 µg anti-PDL1 i.p. on days 0 and 3 and then weekly until day 100. Tumor size and tumor mass are presented as mean ± SEM and mean ± SD, respectively. Statistical difference was determined by log-rank (Mantel-Cox) test E and F, by the two-way ANOVA method followed by following Bonferoni’s multiple correction testing G and K, or by the Mann Whitney test I and L. *0.05 > P ≥ 0.01, **0.01 > P ≥ 0.001, ***0.001 > P. NS non-significant. Black, white, grey, and red scale bar 50, 500, 100, and 250 μm, respectively